Vaccine for treating and/or preventing type I diabetes and application thereof

A technology for diabetes and vaccines, applied in vaccines for the treatment and/or prevention of type 1 diabetes and its application field, which can solve the problems of suppressing organ failure, unreasonable curative effect, toxic and side effects, etc., and achieve the effect of inhibiting the occurrence of type 1 diabetes

Active Publication Date: 2017-05-17
ADVACCINE SUZHOU BIOPHARMACEUTICALS CO LTD
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Because these drugs are non-specific immunosuppressants, the curative effect is unreasonable, and the use of large doses of immunosuppressants has its toxic and side effects. lead to suppressed organ failure risk

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Vaccine for treating and/or preventing type I diabetes and application thereof
  • Vaccine for treating and/or preventing type I diabetes and application thereof
  • Vaccine for treating and/or preventing type I diabetes and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0083] Embodiment 1, NOD mouse drug dose-effect experiment

[0084] 1. Immunization of NOD mice

[0085] 1. Immunization with a pharmaceutical composition composed of human insulin (Novolin R) and dexamethasone

[0086] The NOD mice were equally divided into 4 groups with 3 mice in each group. On the 1st, 4th, and 7th days, the pharmaceutical composition was subcutaneously injected into the abdomen: each mouse in the first group (10+10 groups) was injected with PBS containing 10 micrograms of human insulin (Novolin R) mixed with 10 micrograms of dexamethasone 100 microliters, the second group (100+100 group) each injected with 100 micrograms of insulin mixed with 100 micrograms of dexamethasone in PBS 100 microliters, the third group (500+100 group) each injected with 500 micrograms of insulin mixed 100 μl of 100 μg dexamethasone in PBS.

[0087] 2. Immunization with a pharmaceutical composition composed of human insulin epitope polypeptide B9-23 and dexamethasone

[0088]...

Embodiment 2

[0103] Example 2, Therapeutic effect test of immediate type Ⅰ diabetes in NOD mice

[0104] 1. Pathogenicity and immunity of NOD mice

[0105] After determining the dose-effect relationship of the drug in Example 1, use NOD mice to induce type I diabetes, and after judging as hyperglycemia (>12mmol), carry out intraperitoneal injection of the pharmaceutical composition (by human insulin (Novolin R) and dexamethasone composition of the pharmaceutical composition). The specific operation is as follows:

[0106] Eighteen NOD mice were intraperitoneally injected with streptozotocin (STZ) (Sigma Aldrige, S0130) 40 mg / kg for 5 consecutive days to induce type 1 diabetes. It was judged as hyperglycemia (>12mmol), (the first injection of STZ was recorded as the first day, and about 10 days later, the immediate type Ⅰ diabetes model of NOD mice was obtained). Group 2 (group 10+10) was injected with 10 micrograms of human insulin mixed with 10 micrograms of dexamethasone in 100 microl...

Embodiment 3

[0121] Embodiment 3, the therapeutic effect test of NOD mouse long-term type Ⅰ diabetes

[0122] After Example 2 proves that the pharmaceutical composition (composed of human insulin (Novolin R) and dexamethasone) has a therapeutic effect on immediate type I diabetes, the therapeutic effect on long-term type I diabetes is evaluated ,details as follows:

[0123] 1. Pathogenicity and immunity of NOD mice

[0124] Sixteen NOD mice were injected intraperitoneally with STZ 40mg / kg for 5 consecutive days to induce type Ⅰ diabetes. After 2 months of onset, the injection therapy was performed. Divided into 2 groups, 8 rats in each group, the first group (incidence group) did not receive treatment, and the second group (treatment group) each injected 100 microliters of PBS mixed with 10 micrograms of human insulin and 10 micrograms of dexamethasone as treatment. Group. On the 1st, 4th, and 7th days, the abdominal subcutaneous injection was performed once, which constituted a course ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a vaccine for treating and / or preventing type I diabetes and an application thereof. The active ingredients of the vaccine are as follows: 1) or 2) or 3): 1) proteantigen of type I diabetes and an immunosuppressor; 2) an epitope peptide of the proteantigen of type I diabetes and the immunosuppressor; and 3) the proteantigen of type I diabetes, the epitope peptide of the proteantigen of type I diabetes and the immunosuppressor, wherein the proteantigen of type I diabetes is at least one of insulin, glutamate decarboxylase and islet amyloid polypeptide; and the immunosuppressor is at least one of dexamethasone, cyclosporin A, tacrolimus, mycophenolate mofetil, azathioprine, prednisone, early-group prednisolone, anti-CD4 monoclonal antibody and anti-C3 monoclonal antibody. The composition can promote Treg proliferation, accelerate secretion of IL-10 and TGF-beta, control the blood glucose level, inhibit the killing action of autoimmune responsive CD8 T cells, inhibit DC cell maturation, and induce immunosuppression so as to effectively treat type I diabetes.

Description

[0001] This application is a divisional application with the application number 201210108159.6, the application date is April 13, 2012, and the invention creation name is "a pharmaceutical composition for treating and / or preventing type 1 diabetes and its application". technical field [0002] The present invention relates to a vaccine for treating and / or preventing type 1 diabetes and its application. Background technique [0003] Experts from the World Health Organization (WHO) predict that diabetes will be a major health crisis in the 21st century, especially in Asia, where its threat is more serious than bird flu and AIDS. WHO estimates that the number of diabetic patients in the world will increase to 200 million by 2010, and will exceed 330 million by 2025. From the analysis of the current situation, in the next 10 years, 60% of all cases in the world will appear in Asia. It was revealed that the Western Pacific region (including China) and Southeast Asia (including I...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/00A61K39/395A61K38/51A61K38/28A61P3/10A61P37/06A61K38/13A61K31/573A61K31/52A61K31/436
CPCA61K31/436A61K31/52A61K31/573A61K38/13A61K38/28A61K38/51A61K39/0008A61K39/3955C12Y401/01015A61K2300/00A61K38/22C07K16/2815C07K2317/76A61K39/39541A61P37/02A61P37/06A61P3/10A61K2039/505
Inventor 王宾郑国兴耿爽王意忠俞庆龄
Owner ADVACCINE SUZHOU BIOPHARMACEUTICALS CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap